Prof.Dr. PRADEEP KUMAR

Dr.Sanjay Kumar Mishra, DR. SRISHTI KHULLAR, Dr. ALOK SATI

Abstract

The aim was to compare the effectiveness and safety of brolucizumab and aflibercept, in treatment-naïve nAMD Indian patients over 48 weeks.

Methods:

A prospective, randomized, single-centre, single-blinded, two-arm comparative study was conducted between Mar 21 to Feb 22. N=114, 56 received brolucizumab (6 mg/50µL) while 58 received aflibercept (2 mg/50µL). 03 initial loading doses at 4-week intervals of both the agents and then respective therapies were given PRN based on the signs of active macular neovascularization..

Results:

Brolucizumab was found to be non-inferior to aflibercept in terms of mean change in BCVA (-0.13 ± 0.21 logMAR vs. -0.10 ± 0.15 logMAR) and reduction in CMT (-112.59 ± 81.23 µm vs. -86.38 ± 71.82 µm), with significant (p<0.0001) lesser number of injections (1.8 ± 1.1 vs. 3.8 ± 1.5). The average ocular side effects were comparable The study suggest non-inferiority of brolucizumab to aflibercept in nAMD while achieving longer inter-injection intervals.

Full Text